A Randomized, Double-masked, Sham-controlled Phase 3b/4 Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy as Indicated in Subjects With Polypoidal Choroidal Vasculopathy

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 21 Jan 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aflibercept (Primary) ; Verteporfin
Indications Polypoidal choroidal vasculopathy; Wet age-related macular degeneration
Focus Therapeutic Use
Acronyms PLANET
Sponsors Bayer

Most Recent Events

14 Jan 2019 Status changed from active, no longer recruiting to completed.
30 Aug 2017 According to a Bayer media release, results from this trial will be presented at the European Society of Retina Specialists (EURETINA) Congress 2017.
23 Aug 2017 This trial has been completed in Germany (End date:07-07-2017).

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight